eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
13.31
+0.95 (7.71%)
Oct 29, 2025, 4:00 PM EDT - Market closed
eXoZymes Employees
eXoZymes had 31 employees as of December 31, 2024. The number of employees increased by 2 or 6.90% compared to the previous year.
Employees
31
Change (1Y)
2
Growth (1Y)
6.90%
Revenue / Employee
n/a
Profits / Employee
-$248,679
Market Cap
111.63M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31 | 2 | 6.90% |
| Dec 31, 2023 | 29 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EXOZ News
- 5 days ago - CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference - Accesswire
- 4 weeks ago - Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees - Accesswire
- 2 months ago - eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today - Accesswire
- 2 months ago - eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST - Accesswire
- 3 months ago - eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity - Accesswire
- 3 months ago - eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months - Accesswire
- 4 months ago - eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing - Accesswire
- 5 months ago - eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast - Accesswire